期刊文献+

AZD2281诱导乳腺癌MDA-MB-231细胞凋亡的实验研究

Experimental study of apoptosis of human breast cancer MDA-MB-231 cell line induced by AZD2281
暂未订购
导出
摘要 目的观察AZD2281对乳腺癌MDA-MB-231细胞株增殖和凋亡的影响,并探讨其可能的机制。方法 MTT法和流式细胞仪法观察不同浓度AZD2281(2.5、5、10 nmol/L)作用于MDA-MB-231细胞24、48、72 h后对细胞增殖、周期分布及细胞凋亡的影响;Western blotting检测经AZD2281处理该细胞24 h后细胞凋亡相关蛋白Bcl-2和caspase-3表达水平的变化。结果 AZD2281可显著抑制MDA-MB-231细胞增殖,且呈时间和剂量依赖性;AZD2281作用于MDA-MB-231细胞24 h后,细胞被阻滞在G0/G1期,并促进其凋亡,且呈剂量依赖性。AZD2281作用MDA-MB-231细胞24 h后,凋亡抑制蛋白Bcl-2的表达呈剂量依赖性下降,而凋亡促进蛋白caspase-3的表达呈剂量依赖性上升。结论 AZD2281能显著抑制MDA-MB-231细胞增殖和促进其凋亡,其作用机制可能是通过上调caspase-3和下调Bcl-2蛋白表达实现的。 Objective To investigate the effects of AZD2281 on proliferation and apoptosis of human breast cancer cell MDA- MB-231 in vitro and the possible mechanisms. Methods Different concentrations of AZD2281 (2. 5, 5, 10 nmol/L) were used to treat MDA-MB-231 cells for 24,48,72 h, and its effects of time and dose were observed. Cell proliferation inhibition rates were measured by MTr assay. The flow cytometry was used to analyze cell-cycle distribution and cell apoptosis. The western blotting was used to detect the expression levels of Bcl-2 and caspase-3. Results The proliferation of MDA-MB-231 cells was inhibited by AZD2281 in a dose-and time-dependent manner. The cell was arrested in the G0/G1 phase by AZD2281 treatment after 24 h, and the cell apoptosis was induced in a dose-dependent manner. AZD2281 could down-regulate the protein expression of Bcl-2 level after treatment with AZD2281 but up- regulate the protein expression level of caspase-3 protein. Conclusion AZD2281 can inhibit the proliferation of human breast cancer cell MDA-MB-231 and induce its apoptosis by down-regulating the expression of Bcl-2 protein and up-regulating the expression of caspase-3 protein.
出处 《临床肿瘤学杂志》 CAS 2015年第7期593-597,共5页 Chinese Clinical Oncology
关键词 乳腺癌 AZD2281 增殖 细胞凋亡 Breast cancer AZD2281 Proliferation Apoptosis
  • 相关文献

参考文献17

  • 1Jemal A,Siegel R, Ward E, et al. Cancer statistics, 2008 [ J ].CA Cancer J Clin, 2008,58(2) :71-96.
  • 2Nofech-Mozes S, Trudeau M, Kahn HK, et al. Patterns of recur-rence in the basal and non-basal subtypes of triple-negative breastcancers[ J]. Breast Cancer Res Treat, 2009, 118(1) : 131-137.
  • 3罗湘,史艳侠,李志铭,张东生,苏争艳,姜文奇.三阴乳腺癌的临床病理特征和预后分析[J].中国癌症杂志,2009,19(7):517-522. 被引量:21
  • 4Carey LA, Perou CM, Livasy CA, et al. Race, breast cancersubtypes, and survival in the Carolina Breast Cancer Study [ J ].JAMA, 2006,295(21): 2492-2502.
  • 5Dawood S, Broglio K, Kau SW, et al. Triple receptor-negativebreast cancer : the effect of race on response to primary systemictreatment and survival outcomes [ J ]. J Clin Oncol, 2009, 27(2):220-226.
  • 6Rottenberg S, Jaspers JE,Kersbergen A,et al. High sensitivityof BRCA1-deficient mammary tumors to the PARP inhibitorAZD2281 alone and in combination with platinum drugs[ J]. ProcNatl Sci USA, 2008,105(44) ; 17079-17084.
  • 7Jemal A, Siegel H, Xu J,et al. Cancer statistics, 2010[ J]. CACancer J Clin, 2010,60(5) : 277-300.
  • 8Foulkes WD, Smith IE, Reis-Filho JS, et al. Triple-negativebreast cancer[J]. N Engl J Med, 2010,363(20) : 1938-1948.
  • 9Podo F, Buydens LM, Degani H, et al. Triple-negative breastcancer: Present challenges and new perspectives[ J]. Mol Oncol,2010,4(3) :209-229.
  • 10Helleday T, Petermann E, Lundin C, et al. DNA repair pathwaysas targets for cancer therapy[ J]. Nat Rev Cancer, 2008, 8(3):193-204.

二级参考文献31

  • 1Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [ J ] . JAMA, 2006, 295(21): 2492-2502.
  • 2Dent R, Trudeau M, Pritchard K J, et M. Triple negative breast cancer: features and patterns of recurrence [ J ] . Clin Cancer Res, 2007, 13(15): 4429-4434.
  • 3Rakha EA, EI-Sayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer [ J].Cancer, 2007, 109(1): 25-32.
  • 4Umemura S, Takekoshi S, Suzuki Y, et al. Estrogen receptornegative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression [ J ] . Oncol Rep, 2005,14(2): 337-343.
  • 5Perez EA, Roche PC, Jenkins RB, et al. Her-2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization [J]. Mayo Clin Proc, 2002, 77(2): 148-154.
  • 6Carlson RW, Moench S J, Hammond ME, et al. fler-2 testing in breast cancer: NCCN Task Force reporl and recommendations [J]. J Natl Compr Cane Netw, 2006, 4(Suppl 3): 1-22.
  • 7Siziopkou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the 7 group of breast tumors that could benefit from EGFR-targeted therapies [ J ] . Breast, 2007, 16(1): 104-107.
  • 8Livasy CA, Karaea G, Nanda R, et al. Phenotypie evaluation of the basal-like subtype of invasive breast carcinoma [J].Mod Pathol, 2006, 19(2): 264-271.
  • 9Rakha EA, Reis Filho J, Ellis IO. Basal-like breast cancer: a critical review [ J ] . J Clin Oncol, 2007, 25(30): 4772-4778.
  • 10Reis-Filho JS, Tutt AN. Triple negative breast cancer: a critical review [ J ] . Histopathology, 2008, 52(1): 108-118.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部